

Complete listing of all claims, with markings and status identifiers
(currently amended claims showing deletions by ~~strike through~~ and additions by underlining)

1-10. (Canceled)

11. (Currently amended) A compound ~~according to claim 3 wherein said compound is~~
according to the formula:

(Aib^{8,35}, Arg^{26,34}, Phe³¹, Pro³⁷, Ser^{38,39})hGLP-1(7-39)-NH₂; (SEQ ID NO:1)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Asn³⁸)hGLP-1(7-38)-NH₂; (SEQ ID NO:2)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ser³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:3)
(Aib^{8,35,37}, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:4)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:5)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:6)
(Aib^{8,35,37}, Arg^{26,34}, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:7)
(Aib^{8,35,37}, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:8)
(Aib^{8,35}, Arg^{26,34}, β-Ala³⁷, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:9)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:10)
(Aib^{8,35,37}, Arg^{26,34}, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:11)
(Aib^{8,35,37}, Arg^{26,34}, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:12)
(Aib^{8,35,37}, Arg^{26,34}, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:13)
(Aib^{8,35,37}, Arg³⁴, Phe³¹, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:14)
(Aib^{8,35,37}, Arg^{26,34}, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:15)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:16)
~~(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ava³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:17)~~
~~(Aib^{8,35,37}, Arg^{26,34}, Ava³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:18)~~
(Aib^{8,35,37}, Arg³⁴, Phe³¹, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:19)
(Aib^{8,35,37}, Arg³⁴, Phe³¹, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:20)
(Aib^{8,35,37}, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:21)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:22)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:23)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:24)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala^{37,38})hGLP-1(7-38) NH₂; (SEQ ID NO:25)

(Aib^{8,35,37}, Arg³⁴, Phe³¹, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:26) or
(Aib^{8,35,37}, Arg³⁴, Phe³¹, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:27)
or a pharmaceutically acceptable salt thereof.

12. (Currently amended) A pharmaceutical composition comprising a compound according to claim [[3]] 11 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

13-27. (Canceled)